Friday, August 8, 2025

MASH (Metabolic dysfunction-associated steatohepatitis)

MASH, previously known as NASH, and MASLD, previously known as NAFLD, are both related to fat buildup in the liver, but MASH is a more severe, inflammatory form. 
 
MASH (Metabolic dysfunction-associated steatohepatitis) is characterized by inflammation and liver cell damage, potentially leading to cirrhosis and liver cancer. MASLD (Metabolic dysfunction-associated steatotic liver disease) is the broader term for fatty liver disease, encompassing cases with and without inflammation. 


New Name:
The name change from NASH to MASH emphasizes the role of metabolic dysfunction (like obesity, insulin resistance, and type 2 diabetes) in the disease's development.

Inflammation and Liver Damage:
MASH is characterized by inflammation and liver cell damage in addition to fat buildup in the liver.  

In essence:
  • NAFLD is now MASLD.
  • NASH is now MASH.
  • MASH is a more severe, inflammatory form of MASLD.
  • Both conditions are linked to metabolic dysfunction. 

What is metabolic dysfunction-associated steatotic liver disease (MASLD)?
MASLD is a general term for a range of conditions characterized by extra fat in liver cells that is not caused by alcohol. It used to be known as nonalcoholic fatty liver disease, or NAFLD. It’s normal for the liver to contain some fat. However, if more than five percent of the liver’s weight is fat, it’s considered a to be a steatotic liver (previously called a fatty liver). There are two different types of steatotic liver disease:

Fibrosis
This fibrosis can progress to cirrhosis, where hard scar tissue replaces an increasingly larger amount of soft healthy liver tissue. Cirrhosis from MASH typically takes years of damage to develop.

Simple steatotic liver
In this form of MASLD, you have fat in your liver, but little or no inflammation of the liver or damage to liver cells. Typically, this form does not progress to cause liver damage.

Metabolic dysfunction-associated steatohepatitis (MASH)
This is the more severe form of MASLD in which you have hepatitis – meaning swelling or inflammation of the liver –– and liver cell damage, in addition to fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver.


What is Metabolic Dysfunction-Associated Steatohepatitis (MASH)?
MASH (metabolic dysfunction-associated steatohepatitis)  is a progression of MASLD in which simple steatosis gets worse and inflammation of the liver occurs.  The medical terms for inflammation (swelling) of the liver is hepatitis.  This is not be be confused with virus-related hepatitis (e.g., hepatitis C).  Liver cell damage may also occur.

Inflammation and cell damage can lead to a condition known as fibrosis, or scarring of the liver.  Over time, fibrosis can get worse. As fibrosis progresses, hardened scar tissue replaces an increasingly larger amount of soft, healthy liver tissue.  When this happens, it is called cirrhosis.  It usually takes many years to develop cirrhosis due to MASH.


How common are MASLD and MASH?
MASLD is the most common chronic liver condition in the United States. It’s estimated that about 25 percent of adults in the U.S. have MASLD. Of those with MASLD, about 20 percent have MASH (five percent of adults in the U.S.). Most people with MASLD have simply fatty liver.

The reason some people with MASLD have simple fatty liver and others get MASH isn’t known, although research suggests that certain genes may play a role.


Monday, June 2, 2025

Kymera Therapeutics (KYMR) : atopic dermatitis potential matches Sanofi/Regeneron's blockbuster Dupixent in early biomarker response

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine.
The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.
  • Sector: Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 208
  • Founded by Bruce Lee Booth and Nello Mainolfi in September 2015 
  • Headquartered in Watertown, Massachusetts
  • https://www.kymeratx.com
IPO: Aug 21, 20

 

 



Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. 

Thursday, March 27, 2025

ADMA Biologics (ADMA)

ADMA Biologics makes human-derived immunoglobulin. Its products treat people whose bodies don't make enough antibodies to ward off illnesses from common viruses. Instead of risking illness, people with primary immunodeficiency receive regular infusions of ADMA's drugs.
  • Sector: Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 685
  • Founded by Adam S. Grossman and Jerrold B. Grossman in 2004  
  • Headquartered in Ramsey, New Jersey
  • https://www.admabiologics.com/
IPO: October 17, 2013
Ticker:  ADMA







ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. 


ADMA's biggest moneymaker, Asceniv. 
ADMA Biologics developed Asceniv in-house. It's a cocktail created from super donors whose plasma has a high level of antibodies capable of handling respiratory syncytial virus, or RSV. RSV leads to cold symptoms in most people, but it can be serious in people with compromised immune systems.

Last year, Asceniv generated $216.7 million in sales. This year, it's expected to bring in $283 million, growing almost 31%. Earnings are also promising. In 2024, ADMA Biologics earned 49 cents per share, flipping from no earnings in the year-earlier period. This year, it's expected to notch a 71-cent profit, up 45%.

Asceniv accounts for slightly more than half of ADMA's total sales. The company also sells Bivigam and Nabi-HB, two products it acquired. Bivigam provides various antibodies found in a healthy immune system, while Nabi-HB protects against hepatitis B in people who've been exposed.